Muscle Relaxants, Central
"Muscle Relaxants, Central" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)
Descriptor ID |
D009125
|
MeSH Number(s) |
D27.505.696.510 D27.505.696.663.700.600 D27.505.954.427.525
|
Concept/Terms |
Muscle Relaxants, Central- Muscle Relaxants, Central
- Central Muscle Relaxants
- Relaxants, Central Muscle
- Centrally Acting Muscle Relaxants
|
Below are MeSH descriptors whose meaning is more general than "Muscle Relaxants, Central".
Below are MeSH descriptors whose meaning is more specific than "Muscle Relaxants, Central".
This graph shows the total number of publications written about "Muscle Relaxants, Central" by people in this website by year, and whether "Muscle Relaxants, Central" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 1 | 2 | 3 |
2018 | 1 | 0 | 1 |
2019 | 3 | 0 | 3 |
2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Muscle Relaxants, Central" by people in Profiles.
-
Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019. J Nippon Med Sch. 2021 Dec 29; 88(6):533-539.
-
Beneficial effects of dantrolene in the treatment of rhabdomyolysis as a potential late complication associated with COVID-19: a case report. Eur J Med Res. 2021 Feb 08; 26(1):18.
-
Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis? Eur Rev Med Pharmacol Sci. 2020 10; 24(19):10228-10238.
-
A Case of Catatonia in a Man With COVID-19. Psychosomatics. 2020 Sep - Oct; 61(5):556-560.
-
Neuroleptic malignant syndrome in a COVID-19 patient. Brain Behav Immun. 2020 08; 88:28-29.
-
Pediatric intrathecal baclofen management during the COVID-19 pandemic in the US and Canada. J Pediatr Rehabil Med. 2020; 13(3):379-384.
-
Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019 04; 31(4):499-502.
-
Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2019 05; 125:247-252.
-
Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review. Anesthesiology. 2019 01; 130(1):41-54.
-
The use ultrasound guided for refilling intrathecal baclofene pump in complicated clinical cases: A practical approach. J Clin Neurosci. 2018 Nov; 57:194-197.